2nd World Companion Diagnostics and Liquid Biopsy Summit APAC | Singapore | November 12-13, 2025

Memo

With rising demand for targeted therapies and testing access, the Asia-Pacific region is becoming a rising player in the co-development and commercialization of drug-diagnostic strategies. In under a year, Singapore has accelerated public-private partnerships to scale genomic testing, China has expanded national reimbursement for liquid biopsies, and Japan has refined its regulatory framework for companion diagnostic approvals. Returning for its second year, the World Liquid Biopsy and Companion Diagnostics Summit APAC will unite 100+ leaders across biopharma, diagnostics, regulation, and healthcare to drive the co-development and commercialization of affordable, scalable, and timely testing solutions. Spanning oncology to neurology, chronic and rare diseases, join this APAC-dedicated forum addressing the full drug-diagnostic co-development journey, where precision partnerships are formed, regional strategies aligned, and precision medicine innovation accelerated for improved patient access across the region. URLs:Brochure: https://go.evvnt.com/3193610-0?pid=5569 Tickets: https://go.evvnt.com/3193610-2?pid=5569  Date and Time: Wed, 12 Nov 2025 07:30 - Thu, 13 Nov 2025 18:00 Venue details: voco Orchard Singapore by IHG, 581 Orchard Road, Singapore, 238883, Singapore Prices:Conference Only - Solution Provider Pricing: USD 3299.00,Conference Only - Industry Pricing: USD 0.50 Speakers: Nannan Zhang Senior Director, Translational and Biomarker Research Abbisko Therapeutics, Arvinjit Singh Regional Medical Therapy Area Lead, Solid Tumors Abbvie, Jack Wong Founder Asia Regulatory Professionals Association, Janise Chevrier-Lee Vyloy Global Medical Affairs Lead, International Markets, MA Global Brand Strategy Astellas Pharma, Ti Hwei How Vice President, Oncology AstraZeneca, Chiaki Kiyokawa PHC Solution Regulatory Affairs Group Chugai Pharmaceuticals, Anita Suresh Director, Genomics and Diagnostic Technologies FIND, Sophie Cui Biomarker IVD, Director Gilead Sciences, Min Qing Director, Oncology Precision Medicine and Diagnostic Johnson and Johnson, Xin Ye Director, Oncology Precision Medicine and Diagnostic Johnson and Johnson, Rainbow Poon Senior Director and Head of Global Clinical Delivery Unit and Oncology Merck KGaA, Yuan-Liang Wang Head of Biology Discovery Department, Senior Scientist OBI Pharma Inc., Nicholas Tan Head of People and Culture SOPHiA GENETICS, Yan Wang Associate Scientific Director, Research Innovation Takeda Pharmaceutical, Ivan Horak Founder and Chief Executive Officer Tikva Allocell, Andreas Stange Senior Vice President TÜV SÜD